Cardiol Therapeutics Class Stock Buy Hold or Sell Recommendation
| CRDL Stock | USD 1.58 0.05 3.27% |
Given the investment horizon of 90 days and your way above-average risk tolerance, our recommendation regarding Cardiol Therapeutics Class is 'Hold'. The recommendation algorithm takes into account all of Cardiol Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Cardiol Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Cardiol and provide practical buy, sell, or hold advice based on investors' constraints. Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
Cardiol |
Execute Cardiol Therapeutics Buy or Sell Advice
The Cardiol recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Cardiol Therapeutics Class. Macroaxis does not own or have any residual interests in Cardiol Therapeutics Class or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Cardiol Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Cardiol Therapeutics Trading Alerts and Improvement Suggestions
| Cardiol Therapeutics generated a negative expected return over the last 90 days | |
| Cardiol Therapeutics may become a speculative penny stock | |
| Cardiol Therapeutics has high historical volatility and very poor performance | |
| Cardiol Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (28.13 K) with profit before overhead, payroll, taxes, and interest of 78.76 K. | |
| Cardiol Therapeutics Class currently holds about 70.45 M in cash with (25.18 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.14. | |
| Cardiol Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: What is HC Wainwrights Forecast for CRDL FY2024 Earnings - MarketBeat |
Cardiol Therapeutics Returns Distribution Density
The distribution of Cardiol Therapeutics' historical returns is an attempt to chart the uncertainty of Cardiol Therapeutics' future price movements. The chart of the probability distribution of Cardiol Therapeutics daily returns describes the distribution of returns around its average expected value. We use Cardiol Therapeutics Class price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Cardiol Therapeutics returns is essential to provide solid investment advice for Cardiol Therapeutics.
| Mean Return | -0.23 | Value At Risk | -5.73 | Potential Upside | 5.62 | Standard Deviation | 3.75 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Cardiol Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Cardiol Stock Institutional Investors
| Shares | Geode Capital Management, Llc | 2024-09-30 | 52.4 K | Bank Of Montreal | 2024-06-30 | 50.1 K | Bmo Capital Markets Corp. | 2024-06-30 | 50.1 K | Marble Harbor Investment Counsel, Llc | 2024-09-30 | 36.9 K | Sontag Advisory Llc | 2024-09-30 | 30.3 K | Arrowstreet Capital Limited Partnership | 2024-06-30 | 29.3 K | Group One Trading, Lp | 2024-06-30 | 28.3 K | Royal Bank Of Canada | 2024-06-30 | 27.1 K | Two Sigma Investments Llc | 24.7 K | Tejara Capital Ltd | 2024-06-30 | 1.7 M | Advisorshares Investments, Llc | 2024-09-30 | 1.2 M |
Cardiol Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 142.6K | 1.1M | 18.0K | (4.5M) | (5.1M) | (5.4M) | |
| Investments | (424.3K) | (40.6K) | (12.9K) | (74.7K) | (101.4K) | (106.5K) | |
| Change In Cash | (9.8M) | 7.1M | 69.9M | (24.4M) | (24.5K) | (23.3K) | |
| Net Borrowings | (20.2K) | (50.5K) | (51.9K) | (53.9K) | (48.5K) | (46.1K) | |
| Free Cash Flow | (11.8M) | (9.2M) | (23.6M) | (27.3M) | (25.2K) | (26.5K) | |
| Depreciation | 150.6K | 229.5K | 220.4K | 219.9K | 248.36 | 235.94 | |
| Other Non Cash Items | 507.7K | 145.0K | 4.2M | 1.9M | (4.2M) | (4.0M) | |
| Capital Expenditures | 424.3K | 40.6K | 12.9K | 74.7K | 64.31 | 61.09 | |
| Net Income | (13.7M) | (20.6M) | (31.6M) | (30.9M) | (28.1K) | (29.5K) | |
| End Period Cash Flow | 7.0M | 14.0M | 83.9M | 59.5M | 34.9K | 33.2K | |
| Change To Netincome | 3.8M | 2.9M | 7.8M | (2.3M) | (2.0M) | (1.9M) |
Cardiol Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Cardiol Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Cardiol Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Cardiol stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.32 | |
β | Beta against Dow Jones | 0.65 | |
σ | Overall volatility | 3.80 | |
Ir | Information ratio | -0.1 |
Cardiol Therapeutics Volatility Alert
Cardiol Therapeutics Class exhibits very low volatility with skewness of 0.46 and kurtosis of 0.8. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cardiol Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cardiol Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Cardiol Therapeutics Fundamentals Vs Peers
Comparing Cardiol Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Cardiol Therapeutics' direct or indirect competition across all of the common fundamentals between Cardiol Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Cardiol Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Cardiol Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Cardiol Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Cardiol Therapeutics to competition |
| Fundamentals | Cardiol Therapeutics | Peer Average |
| Return On Equity | -1.08 | -0.31 |
| Return On Asset | -0.54 | -0.14 |
| Current Valuation | 116.38 M | 16.62 B |
| Shares Outstanding | 81.6 M | 571.82 M |
| Shares Owned By Insiders | 3.91 % | 10.09 % |
| Shares Owned By Institutions | 9.50 % | 39.21 % |
| Number Of Shares Shorted | 893.32 K | 4.71 M |
| Price To Book | 16.79 X | 9.51 X |
| Price To Sales | 1,069 X | 11.42 X |
| Gross Profit | 78.76 K | 27.38 B |
| EBITDA | (29.59 M) | 3.9 B |
| Net Income | (28.13 K) | 570.98 M |
| Cash And Equivalents | 70.45 M | 2.7 B |
| Cash Per Share | 1.14 X | 5.01 X |
| Total Debt | 174.34 K | 5.32 B |
| Debt To Equity | 0 % | 48.70 % |
| Current Ratio | 6.48 X | 2.16 X |
| Book Value Per Share | 0.43 X | 1.93 K |
| Cash Flow From Operations | (25.18 K) | 971.22 M |
| Short Ratio | 1.37 X | 4.00 X |
| Earnings Per Share | (0.38) X | 3.12 X |
| Target Price | 12.42 | |
| Beta | 0.7 | -0.15 |
| Market Capitalization | 124.85 M | 19.03 B |
| Total Asset | 36.7 M | 29.47 B |
| Retained Earnings | (142.58 M) | 9.33 B |
| Working Capital | 51.63 M | 1.48 B |
| Net Asset | 36.7 M |
Cardiol Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Cardiol . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Cardiol Therapeutics Buy or Sell Advice
When is the right time to buy or sell Cardiol Therapeutics Class? Buying financial instruments such as Cardiol Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Cardiol Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Measuring and Control Equipment Thematic Idea Now
Measuring and Control Equipment
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Measuring and Control Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Measuring and Control Equipment Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Cardiol Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.38) | Return On Assets (0.54) | Return On Equity (1.08) |
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.